It is learned on February 15 from multi sources (China Securities Journal etc) that recently, Baidu has completed the acquisition of GBI, a Chinese medical information data provider. The core asset of GBI is a large amount of medical device data.
GBI mainly has three databases, namely the SOURCE global drug database, the METRIX researcher database, and the DEVINT medical device database. Among them, the SOURCE global database includes global clinical trial progress, drug patents, targets, etc. before drug listing; Post-launch bidding, medical insurance/essential drug catalog, medical insurance dual-channel allocation agencies and other data; And, analysis of drug declaration, access layout, batch release, etc.
The METRIX researcher database can provide pharmaceutical companies with the best researcher recommendations by collecting and tracking information on researchers, clinical trials, and scientific research projects.
The DEVINT medical device database mainly absorbs the technical data of the device industry.
Baidu said that through the combination of GBI and its latest AI product Wenxin Yiyan, Baidu will bring greater influence in the field of medical business solution services, and GBI will also become a key growth engine for Baidu’s big health business group (HCG).
At the same time, this also means that Baidu’s artificial intelligence (AI) application model in the medical industry has obtained another piece of the puzzle.